| Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions -> Monitor Keywords |
|
|
  Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditionsUSPTO Application #: 20060292613Title: Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma. (end of abstract) Agent: Darby & Darby P.C. - New York, NY, US Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran USPTO Applicaton #: 20060292613 - Class: 435006000 (USPTO) Related Patent Categories: Chemistry: Molecular Biology And Microbiology, Measuring Or Testing Process Involving Enzymes Or Micro-organisms; Composition Or Test Strip Therefore; Processes Of Forming Such Composition Or Test Strip, Involving Nucleic Acid The Patent Description & Claims data below is from USPTO Patent Application 20060292613. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit of U.S. provisional application No. 60/367,513 filed Mar. 27, 2002. FIELD OF THE INVENTION [0002] The invention relates to methods and compounds for the prevention and/or treatment of ocular hypertension or elevated intraocular pressure, and related conditions such as glaucoma. BACKGROUND OF THE INVENTION Glaucoma and Intraocular Pressure [0003] Glaucoma is characterized by optic nerve head excavation which can lead to loss of peripheral vision and sometimes loss of central vision. Glaucoma is the second leading cause of vision loss worldwide; an estimated 66.8 million people will have primary glaucoma and 6.7 million will be bilaterally blind due to this disorder. In the United States, glaucoma is the second leading cause of permanent blindness and the leading cause among African Americans. While glaucoma is treatable and vision loss can be prevented, once vision loss occurs it is irreversible. Elevated intraocular pressure (IOP) is a major risk factor for the development of glaucoma, but it is not found in all patients with the disease (Sommer, A. et al., Arch. Ophthalmol. 109: 1090-1095 (1991)). Glaucoma associated with elevated IOP is divided into three major categories: open angle, closed angle and developmental. Each of these categories is further divided into primary and secondary forms, and by the age of onset. Drugs that lower IOP, such as latanoprost, unoprost, timolol which target prostaglandin F.sub.2a.alpha. and .beta..sub.2 adrenergic receptors are being currently used to prevent and delay ocular degeneration in glaucomatous patients. [0004] There is therefore a continued need to identify and characterize targets and in turn products for the prevention and treatment of ocular disorders, such as glaucoma. SUMMARY OF THE INVENTION [0005] The invention relates to R-14 nucleic acids and polypeptides and compounds capable of lowering intraocular pressure and uses thereof. [0006] Accordingly, in an aspect, the invention provides a substantially pure peptide compound of Formula I:Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8- -Z.sub.2 I wherein: [0007] X.sub.1 is selected from the group consisting of Phe, His, Ile and related amino acids; [0008] X.sub.2 is selected from the group consisting of Ser, Ile, Phe and related amino acids [0009] X.sub.3 is selected from the group consisting of Leu, Ile, Asp and related amino acids [0010] X.sub.4 is selected from the group consisting of Thr, Cys, Ser and related amino acids possessing side chains containing sulfhydryl, hydroxyl or H-bond forming groups; [0011] X5 is selected from the group consisting of Gln, Ser, Thr and related amino acids; [0012] X.sub.6 is selected from the group consisting of Lys, Pro, Glu and related amino acids; [0013] X.sub.7 is selected from the group consisting of Tyr, Leu, Cys and related amino acids; [0014] X.sub.8 is selected from the group consisting of Cys, Arg, Trp and related amino acids; [0015] Z.sub.1 is an N-terminal group of the formula H.sub.2N--, RHN--or, RRN--; Z.sub.2 is a C-terminal group of the formula --C(O)OH, --C(O)R, --C(O)OR, --C(O)NHR, --C(O)NRR; [0016] R at each occurrence is independently selected from (C.sub.1-C.sub.6) alkyl, (C.sub.1-C.sub.6) alkenyl, (C.sub.1-C.sub.6) alkynyl, substituted (C.sub.1-C.sub.6) alkyl, substituted (C.sub.1-C.sub.6) alkenyl, or substituted (C.sub.1-C.sub.6) alkynyl; and [0017] "-" is a covalent linkage. [0018] The invention further provides a substantially pure synthetic peptide compound or recombinant peptide compound, said compound having a domain of Formula II:-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X5-X.sub.6-X.sub.7-X.sub.8- II wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, X.sub.7, X.sub.8 and "-" are as defined above. [0019] In embodiments, the compound is selected from the group consisting of: FSLTQKYC; HIICSPLR; and IFDSTECW. In embodiments, the domain is selected from the group consisting of: FSLTQKYC; HIICSPLR; and IFDSTECW. [0020] The invention further provides a method of lowering intraocular pressure in a subject, said method comprising administering to said subject an effective amount of the above-mentioned compound. [0021] The invention further provides a method of treating in a subject a condition associated with elevated intraocular pressure, said method comprising administering to said subject an effective amount of the above-mentioned compound. [0022] In embodiments, the methods comprise administering said compound to an eye of said subject. [0023] The invention further provides a pharmaceutical composition comprising the above-mentioned compound in admixture with a pharmaceutically acceptable carrier. In an embodiment, the composition is formulated for administration to an eye of a subject. [0024] The invention further provides a commercial package comprising the above-mentioned compound together with instructions for its use. In embodiments, the use is selected from the group consisting of: (a) lowering intraocular pressure in a subject; and (b) treating a condition associated with elevated intraocular pressure. [0025] The invention further provides an isolated nucleic acid comprising a sequence that encodes the above-mentioned domain. The invention further provides a vector comprising the nucleic acid operably-linked to a transcriptional regulatory element. The invention further provides a host cell comprising the vector. [0026] The invention further provides a method of producing the above-mentioned peptide compound, comprising culturing the above-mentioned host cell under conditions permitting expression of the peptide compound. [0027] The invention further provides an isolated nucleic acid comprising a sequence that encodes a polypeptide comprising at least 278 amino acids of SEQ ID NO: 2. In an embodiment, the polypeptide comprises SEQ ID NO: 2. In an embodiment, the nucleic acid comprises SEQ ID NO: 1 or a sequence substantially identical thereto. [0028] The invention further provides a substantially pure polypeptide comprising at least 278 consecutive amino acids of SEQ ID NO: 2. In a further embodiment, the polypeptide comprises SEQ ID NO: 2. [0029] The invention further provides a vector comprising the above-mentioned nucleic acid operably linked to a transcriptional regulatory element. The invention further provides a host cell comprising the above-mentioned vector. [0030] The invention further provides a method of producing the above-mentioned polypeptide, comprising culturing the above-mentioned host cell under conditions permitting the expression of the polypeptide. Continue reading... Full patent description for Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions patent application. Patent Applications in related categories: 20080182236 - Asthma susceptibility locus - The present invention describes a susceptibility locus which is functionally related to asthma. The locus maps within human chromosome 7p15-p14. The invention also describes a novel human gene, GPRA. The invention provides diagnostic methods and materials for analysing allelic variation in said locus and the GPRA gene. The invention also ... 20080182237 - Lung cancer-related nucleic acids - Described are polynucleotides associated with lung cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of lung cancer. Also described are methods that can be used to identify modulators of the disease-associated polynucleotides. Also ... ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions or other areas of interest. ### Previous Patent Application: Methods and compositions for analysis of microrna Next Patent Application: Methods for genotyping with selective adaptor ligation Industry Class: Chemistry: molecular biology and microbiology ### FreshPatents.com Support Thank you for viewing the Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions patent info. IP-related news and info Results in 1.94889 seconds Other interesting Feshpatents.com categories: Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , |
||
